Crizotinib: all 84 studies that test it

Page 1 of 1. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.

• Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomaRecruitingNCT07804186Phase 3
• Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingNCT06563999Phase 2
• Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2
• ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell CarcinomaRecruitingNCT05014464Phase 2
• Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom TrialRecruitingNCT04693468Phase 1
• PLATFORM Study of Precision Medicine for Rare TumorsRecruitingNCT04423185Phase 2
• Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruitingNCT04322890Phase 2
• Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLCRecruitingNCT04322578Phase 2
• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)Active, not recruitingNCT06360575Phase 2Results posted
• Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)Active, not recruitingNCT06357975Phase 2Results posted
• Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)Active, not recruitingNCT04439266Phase 2Results posted
• Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)Active, not recruitingNCT04439253Phase 2Results posted
• Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomasCompletedNCT04283669Phase 2Results posted
• Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerTerminatedNCT03737994Phase 2Results posted
• Long Term Safety Observation of Crizotinib in Chinese NSCLC PopulationTerminatedNCT03672643Phase 4Results posted
• A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive CancerCompletedNCT03194893Phase 3Results posted
• Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung CancerCompletedNCT03088930Phase 2Results posted
• Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has ProgressedCompletedNCT02761057Phase 2Results posted
• LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial CancerTerminatedNCT02612194Phase 2Results posted
• Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)TerminatedNCT02584634Phase 1/2Results posted
• Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer PatientsTerminatedNCT02511184Phase 1Results posted
• Crizotinib in High-Risk Uveal Melanoma Following Definitive TherapyCompletedNCT02223819Phase 2Results posted
• S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After CrizotinibTerminatedNCT02134912Phase 2Results posted
• A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid TumorsCompletedNCT01999972Phase 1Results posted
• Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell LymphomaCompletedNCT01979536Phase 2Results posted
• Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLCCompletedNCT01945021Phase 2Results posted
• Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung CancerTerminatedNCT01822496Phase 2Results posted
• A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer PatientsCompletedNCT01639001Phase 3Results posted
• Hepatic Impairment Study For Crizotinib In Advanced Cancer PatientsCompletedNCT01576406Phase 1Results posted
• Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated CapsuleCompletedNCT01297595Phase 1Results posted
• A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066CompletedNCT01250730Phase 1Results posted
• A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy VolunteersCompletedNCT01168934Phase 1Results posted
• Bioequivalence And Food Effect Study Comparing The Commercial Formulation Of Crizotinib To Its Clinical Study Formulations And Commercial Formulation With Or Without Food In Healthy VolunteersCompletedNCT01154218Phase 1Results posted
• Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy VolunteersCompletedNCT01149785Phase 1Results posted
• Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy VolunteersCompletedNCT01147055Phase 1Results posted
• Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)TerminatedNCT01121588Phase 1Results posted
• A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung CancerCompletedNCT01121575Phase 1Results posted
• Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male VolunteersCompletedNCT01082380Phase 1Results posted
• Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung CancerCompletedNCT00965731Phase 1Results posted
• Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaCompletedNCT00939770Phase 1/2Results posted
• Relative Drug Exposures Of Two Formulations of PF-02341066CompletedNCT00939731Phase 1Results posted
• An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) GeneCompletedNCT00932893Phase 3Results posted
• An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) GeneCompletedNCT00932451Phase 2Results posted
• A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced CancerCompletedNCT00585195Phase 1Results posted
• IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaActive, not recruitingNCT05987332Phase 2/3
• Crizotinib Continuation Clinical StudyActive, not recruitingNCT05160922Phase 4
• Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)CompletedNCT04856293Phase 1
• Study of Crizotinib for ROS1 and MET Activated Lung CancerCompletedNCT04084717Phase 2
• Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial CancerTerminatedNCT04030429Phase 2
• Study of Crizotinib in Children and Adolescents With Myofibroblastic TumorsStatus unknownNCT03874273Phase 2/3
• Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCLStatus unknownNCT03707847Phase 4
• Phase II Umbrella Study Directed by Next Generation SequencingStatus unknownNCT03574402Phase 2
• A+C in Metastatic Lung Adenocarcinoma CancerStatus unknownNCT02946359Phase 2
• National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedNCT02664935Phase 2
• Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2
• Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)Status unknownNCT02499614Phase 2
• A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With CrizotinibWithdrawnNCT02487316Phase 4
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line ChemotherapyCompletedNCT02435108Phase 2
• Pilot Study of Crizotinib in Relapsed ALK+ LymphomasCompletedNCT02419287Phase 2
• Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver MutationsWithdrawnNCT02277457Early Phase 1
• Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed GlioblastomaCompletedNCT02270034Phase 1
• Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate CancerCompletedNCT02207504Phase 1
• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)Active, not recruitingNCT02201992Phase 3
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruitingNCT02194738Not applicable
• EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung CancerCompletedNCT02183870Phase 2
• CRIZENT: Crizotinib and Sunitinib in Metastatic Breast CancerTerminatedNCT02074878Phase 1
• Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1CompletedNCT02034981Phase 2
• A Study To Taste Three New Types Of Crizotinib Formulation In Comparison Of An Oral Solution And To Measure The Amount Of Crizotinib In The Body After These Formulations Are Orally Given, Relative To Capsule FormulationCompletedNCT02006277Phase 1
• Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung CancerCompletedNCT01998126Phase 1
• Dasatinib and Crizotinib in Advanced CancerCompletedNCT01744652Phase 1
• A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With CrizotinibCompletedNCT01712217Phase 1/2
• Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)CompletedNCT01644773Phase 1
• Drug Drug Interaction Study Of Crizotinib With Esomeprazole.CompletedNCT01549574Phase 1
• Pazopanib or Pemetrexed and Crizotinib in Advanced CancerTerminatedNCT01548144Phase 1
• Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF MutationsCompletedNCT01531361Phase 1
• CREATE: Cross-tumoral Phase 2 With CrizotinibCompletedNCT01524926Phase 2
• A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung CancerWithdrawnNCT01500824Phase 2
• A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.WithdrawnNCT01441388Phase 1
• -02341066 and PF-00299804 for Advanced Non-Small Cell Lung CancerTerminatedNCT01441128Phase 1
• A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal FunctionCompletedNCT01419041Phase 1
• A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult VolunteersCompletedNCT01125904Phase 1

← Crizotinib overview